Prior experimental (non-Food and Drug Administration [FDA] approved) therapies and immunotherapies are allowed; patients must not have received these therapies for 4 weeks prior to the initiation of study treatment and must have full recovery from any acute effects of these therapies
Prior experimental (non-Food and Drug Administration [FDA] approved) therapies and immunotherapies are allowed; patients must not have received these therapies for 3 weeks prior to the initiation of study treatment and must have full recovery from any acute effects of these therapies
More than 4 prior chemotherapy regimens; note: repeat use of regimens count as 1 prior regimen; switching front-line therapy regimens (for example, from intraperitoneal to intravenous therapy) for reasons other than progression will count as 1 prior therapy; bevacizumab and other targeted agents will count in the total number of prior regimens; vaccine therapies will not count in the total of prior therapies
Patients may have an unlimited number of prior therapy regimens
Prior therapy is allowed; patients may have received any number of prior lines of therapy, including treatment with a BRAF and/or MEK inhibitor
There is no limitation in the number of prior lines of therapy
There is no limit to the number of prior lines of treatment a patient has received
Patients may have had treatment for an unlimited number of prior relapses
No more than 3 prior regimens for large cell component (e.g. one induction and two salvage therapies); monoclonal antibody alone or involved field/involved site radiotherapy do not count as lines of therapy
Any number of prior therapies is allowed
Any number of prior therapies are allowed
Any number of prior therapies are allowed
Any number of prior lines of therapy
There is no limit to the number of prior lines of treatment a patient has received
1-2 prior regimens (including primary therapy); hormonal therapies (e.g., tamoxifen, aromatase inhibitors) will not count toward the prior regimen limit
No limitations on prior therapies
For the dose escalation cohort, patients may have received any number of prior therapies
